Evidence map›Paper›PMID 42388580›Full record

ArticleCancer diagnosis & prognosis

From Ascites to Malignant Peritoneal Mesothelioma: The Diagnostic Workup of a Rare Tumor.

Mirko Nastasi, Chiara Ferrante, Giuliana Michelis, Enrica Branca, Manuel Ventura, Silvia Novello, Emanuela Laurita

Abstract read
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mirko NastasiDepartment of Oncology, San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy.
Chiara FerranteDepartment of Internal Medicine, Ospedale di Rivoli, Turin, Italy.
Giuliana MichelisDepartment of Internal Medicine, Ospedale di Rivoli, Turin, Italy.
Enrica BrancaDepartment of Internal Medicine, Ospedale di Rivoli, Turin, Italy.
Manuel VenturaDepartment of Internal Medicine, Ospedale di Rivoli, Turin, Italy.
Silvia NovelloDepartment of Oncology, San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy.
Emanuela LauritaDepartment of Internal Medicine, Ospedale di Rivoli, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: Ascites is a common clinical manifestation of a wide spectrum of heterogeneous underlying conditions. All possible causes of ascites should be considered in the differential diagnosis to ensure an appropriate diagnostic workup. Among the rare causes, malignant peritoneal mesothelioma must be considered, as its diagnosis is particularly challenging. Case Report: We present the case of a 77-year-old female who developed ascites and lower-quadrant abdominal pain. She had no prior history of cancer and no documented occupational exposure to asbestos or other known carcinogens. After exclusion of the principal benign and malignant causes of ascites, we performed a biopsy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). The final diagnosis was primary malignant peritoneal mesothelioma, an extremely rare tumor. Conclusion: This case highlights the complexity of the differential diagnosis. The diagnostic work-up for peritoneal mesothelioma must integrate the patient's clinical history, physical examination, tumor markers, and imaging findings. Biomarkers such as mesothelin and advanced imaging modalities including PET/CT assume an increasingly important role in staging and in distinguishing peritoneal disease entities.

Indexed as

ascitesdifferential diagnosisFDG-PET/TCMalignant peritoneal mesotheliomarare tumortumor markers

Identifiers

PMID42388580
PMCPMC13322104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.